|
|||||
|
|
Clinical performance of the Food and Drug Administration–Approved high‐risk HPV test for the detection of high‐grade cervicovaginal lesions |
|
| Authors: | Haijun Zhou MD PhD Roxanne R. Mody MD Eric Luna CT Donna Armylagos CT Jiaqiong Xu PhD Mary R. Schwartz MD Dina R. Mody MD Yimin Ge MD |
| Affiliation: | 1. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas;2. Department of Obstetrics and Gynecology, St Joseph's Hospital, Denver, Colorado;3. BioReference Laboratories, Houston, Texas;4. Center for Biostatistics, Houston Methodist Hospital Research Institute, Houston, Texas;5. Weill Medical College of Cornell University, New York, New York |
| Abstract: | |
| Keywords: | College of American Pathologists (CAP) benchmark cotesting high‐grade cervicovaginal lesion human papillomavirus (HPV) test Papanicolaou (Pap) test |